InspireMD: A Recall, a Pivot, and a Triple-Threat Regulatory Calendar
International growth and deep cost cuts buy time as three regulatory catalysts approach.
NSPR · Earnings Call · 2026-08-17
InspireMD came out of its second quarter looking like a company in retreat, but the numbers tell a more nuanced story. CEO Marvin Slosman opened the call by framing the quarter: “Notwithstanding our temporary absence from the U.S. market, our total revenue was essentially unchanged from the second quarter of last year.” — Marvin Slosman, Chief Executive Officer · 2026-08-17 That flatness is remarkable given that the voluntary recall of the CGuard Prime 135 delivery system forced a stop on U.S. sales in early May. The company booked a $734,000 customer credit and a $612,000 inventory impairment, dragging GAAP gross margin to -43.7%. Yet the international business – which uses the original CGuard delivery system – grew 21% to $2.1M. CFO Mike Lawless highlighted that: “International revenue was $2.1 million, representing growth of 21% versus the same quarter a year ago.” — Michael Lawless, Chief Financial Officer · 2026-08-17
The recall decision itself was rooted in a long-term view. On the prior earnings call, Slosman explained: “You can't lead in a market of this size, scale and transition without 100% confidence in both the implant and the delivery system.” — Marvin Slosman, Chief Executive Officer · 2026-05-04 He added: “we felt that this was the right time to make it so that we can move forward in an unencumbered way of taking advantage of a market shift candidly to stenting that has been on the docket for the last 20 years.” — Marvin Slosman, Chief Executive Officer · 2026-05-04
A Triple-Threat Regulatory Calendar
The company's near-term value hinges on three decisions from the FDA. The most imminent are for the CGuard Prime 80 platform (which would add TCAR capability, essentially doubling addressable market) and the original CGuard delivery system for CAS. Both are now expected in Q4 2026, a slight slip from prior guidance that Slosman attributed to being "realistic about the regulatory time frames." The company said on the call: “all signals point to potential approval in the fourth quarter” — Marvin Slosman, Chief Executive Officer · 2026-08-17 – a carefully hedged hope. A third catalyst, the redesigned CGuard Prime 135 for CAS, is on track for first-half 2027 with potential acceleration. The company also enrolled the first patient in CGUARDIANS III for its SwitchGuard neuroprotection system. Taken together, these form a coherent TCAR strategy that would let InspireMD cover both CAS and TCAR procedures, a market of roughly 75,000 annual stenting procedures in the U.S.Cost Discipline and a Leaner Engine
To fund that runway, the company is cutting aggressively. CFO Mike Lawless announced:That translates into a restructuring charge of $0.9-1.2M in Q3, with full benefit expected in Q4. The cuts are aimed at preserving commercial readiness – keeping the sales team intact so that a relaunch can be immediate. "We are striking a balance," Slosman said, “we're trying to strike a balance in maintaining the commercial readiness to do so.” — Marvin Slosman, Chief Executive Officer · 2026-08-17 The urgency is clear from the balance sheet. As of Q1 2026, free cash flow was -$15M for the quarter, and cash and equivalents fell from $54.2M at end-2025 to $30.4M by mid-2026. Without the $9M annual savings, the runway would be uncomfortably short. The company is also rethinking its international pricing to wean off low-margin OUS sales and shift toward higher-margin U.S. relaunch. The stock has already reacted to the turbulence: in the last 90 days, NSPR is down 30% and sits 33% below its April peak. But the call sketched a path that, if the FDA delivers as hinted, could turn 2027 into a inflection year. The recall will be remembered as a necessary pause – not a strategic pivot – if these regulatory dominoes fall.we have proactively taken actions to reduce our cost structure and improve our financial flexibility and operational efficiency... a workforce reduction action initiated in the third quarter that reduces the number of positions in our organization by almost 20% and saves the company approximately $9 million on an annual basis.